Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30298
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Majem, Margarita | - |
dc.contributor.author | Goldman, Jonathan W | - |
dc.contributor.author | John, Thomas | - |
dc.contributor.author | Grohe, Christian | - |
dc.contributor.author | Laktionov, Konstantin | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Kato, Terufumi | - |
dc.contributor.author | Vu, Huu Vinh | - |
dc.contributor.author | Lu, Shun | - |
dc.contributor.author | Li, Shanqing | - |
dc.contributor.author | Lee, Kye Young | - |
dc.contributor.author | Akewanlop, Charuwan | - |
dc.contributor.author | Yu, Chong-Jen | - |
dc.contributor.author | de Marinis, Filippo | - |
dc.contributor.author | Bonanno, Laura | - |
dc.contributor.author | Domine, Manuel | - |
dc.contributor.author | Shepherd, Frances A | - |
dc.contributor.author | Atagi, Shinji | - |
dc.contributor.author | Zeng, Lingmin | - |
dc.contributor.author | Kulkarni, Dakshayini | - |
dc.contributor.author | Medic, Nenad | - |
dc.contributor.author | Tsuboi, Masahiro | - |
dc.contributor.author | Herbst, Roy S | - |
dc.contributor.author | Wu, Yi-Long | - |
dc.date.accessioned | 2022-06-23T00:35:09Z | - |
dc.date.available | 2022-06-23T00:35:09Z | - |
dc.date.issued | 2022-06-01 | - |
dc.identifier.citation | Clinical cancer research : an official journal of the American Association for Cancer Research 2022; 28(11): 2286-2296 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/30298 | - |
dc.description.abstract | In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). We report health-related quality of life (HRQoL) outcomes from ADAURA. Patients randomized 1:1 received oral osimertinib 80 mg or placebo for 3 years or until recurrence/discontinuation. HRQoL (secondary endpoint) was measured using the Short Form-36 (SF-36) health survey at baseline, 12, and 24 weeks, then every 24 weeks until recurrence or treatment completion/discontinuation. Exploratory analyses of SF-36 score changes from baseline until week 96 and time to deterioration (TTD) were performed in the overall population (stage IB-IIIA; N = 682). Clinically meaningful changes were defined using the SF-36 manual. Baseline physical/mental component summary (PCS/MCS) scores were comparable between osimertinib and placebo (range, 46-47) and maintained to Week 96, with no clinically meaningful differences between arms; difference in adjusted least squares (LS) mean [95% confidence intervals (CI), -1.18 (-2.02 to -0.34) and -1.34 (-2.40 to -0.28), for PCS and MCS, respectively. There were no differences between arms for TTD of PCS and MCS; HR, 1.17 (95% CI, 0.82-1.67) and HR, 0.98 (95% CI, 0.70-1.39), respectively. HRQoL was maintained with adjuvant osimertinib in patients with stage IB-IIIA EGFRm NSCLC, who were disease-free after complete resection, with no clinically meaningful differences versus placebo, further supporting adjuvant osimertinib as a new treatment in this setting. See related commentary by Patil and Bunn, p. 2204. | en |
dc.language.iso | eng | |
dc.title | Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Clinical cancer research : an official journal of the American Association for Cancer Research | en |
dc.identifier.affiliation | Medical Oncology | en |
dc.identifier.affiliation | Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.. | en |
dc.identifier.affiliation | David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California.. | en |
dc.identifier.affiliation | Klinik für Pneumologie-Evangelische Lungenklinik Berlin Buch, Berlin, Germany.. | en |
dc.identifier.affiliation | Federal State Budgetary Institution "N.N.Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russia.. | en |
dc.identifier.affiliation | Department of Oncology, Asan Medical Center, Seoul, South Korea.. | en |
dc.identifier.affiliation | Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.. | en |
dc.identifier.affiliation | Department of Thoracic Surgery, Choray Hospital, Ho Chi Minh City, Vietnam.. | en |
dc.identifier.affiliation | Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.. | en |
dc.identifier.affiliation | Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.. | en |
dc.identifier.affiliation | Precision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul, Republic of Korea.. | en |
dc.identifier.affiliation | Division of Medical Oncology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.. | en |
dc.identifier.affiliation | Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch and National Taiwan University College of Medicine, Taipei, Taiwan.. | en |
dc.identifier.affiliation | Thoracic Oncology Division, European Institute of Oncology (IEO), IRCCS, Milan, Italy.. | en |
dc.identifier.affiliation | Medical Oncology 2, Istituto Oncologico Veneto (IOV), IRCCS, Padua, Italy.. | en |
dc.identifier.affiliation | Department of Oncology, Hospital Universitario Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.. | en |
dc.identifier.affiliation | Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Center and the University of Toronto, Toronto, Ontario, Canada.. | en |
dc.identifier.affiliation | Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.. | en |
dc.identifier.affiliation | Late Oncology Statistics, AstraZeneca, Gaithersburg, Maryland.. | en |
dc.identifier.affiliation | Late Oncology R&D, AstraZeneca, Cambridge, United Kingdom.. | en |
dc.identifier.affiliation | AstraZeneca Oncology Business Unit, Academy House, Cambridge, United Kingdom.. | en |
dc.identifier.affiliation | Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.. | en |
dc.identifier.affiliation | Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut.. | en |
dc.identifier.affiliation | Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.. | en |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/35012927/ | en |
dc.identifier.doi | 10.1158/1078-0432.CCR-21-3530 | en |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0002-9919-7485 | en |
dc.identifier.orcid | 0000-0002-4925-8243 | en |
dc.identifier.orcid | 0000-0003-3399-5342 | en |
dc.identifier.orcid | 0000-0003-1065-8095 | en |
dc.identifier.orcid | 0000-0002-5853-1424 | en |
dc.identifier.orcid | 0000-0001-6872-2403 | en |
dc.identifier.orcid | 0000-0003-4687-5593 | en |
dc.identifier.orcid | 0000-0003-1022-3745 | en |
dc.identifier.orcid | 0000-0001-5218-4970 | en |
dc.identifier.orcid | 0000-0002-1128-434X | en |
dc.identifier.orcid | 0000-0003-1876-7069 | en |
dc.identifier.orcid | 0000-0002-3611-0258 | en |
dc.identifier.pubmedid | 35012927 | |
local.name.researcher | John, Thomas | |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | Journal Article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.